Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals Limited (“Centessa”), a wholly-owned subsidiary of Eli Lilly and Company (“Lilly”), has achieved a late-stage development milestone associated with its selective orexin receptor 2 (OX2R) agonist portfolio. This milestone triggers a payment of US$8.6 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment
YahooyesterdayLLY
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL,...
YahooyesterdayLLY
Eli Lilly Just Announced a Major Acquisition. Here's What It Means.
The drug giant added to its immunotherapy portfolio.
YahooyesterdayLLY
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
YahooyesterdayLLY
Lilly’s Record Stock Price Is Hiding an Even Bigger Opportunity
Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead.
YahooyesterdayLLY
Peptide innovator says the drug class is due for a rethink
Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption.
Yahoo2 days agoLLY
Top 25 High-Growth Dividend Stocks For September 2026
The September 2026 Top 25 High-Growth Dividend Stocks list targets quality companies trading below intrinsic value with strong long-term return potential.
SeekingAlpha2 days agoLLY
Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications
FDA warns of risks from unapproved compounded GLP-1 drugs including semaglutide and tirzepatide amid rising adverse event reports.
Benzinga2 days agoLLY
This New Zepbound Study Could Be Great News for Eli Lilly Investors
The high-flying healthcare leader looks unstoppable right now.
Yahoo2 days agoLLY
Novo Nordisk Trades Nearly 58% Below GF Value as Wegovy Pill Launches in Germany
Germany becomes the first EU market for oral Wegovy, testing Novo's early lead as Eli Lilly expands.
Yahoo2 days agoLLY
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal
LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.
Yahoo2 days agoLLY
Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet
Employer coverage of GLP-1 drugs is collapsing heading into 2027, but the FDA just gave Eli Lilly a specific piece of ammunition that could change the conversation in payer meetings for at least one slice of that market.
Yahoo3 days agoLLY
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 1:50 p.m. Eastern time.
Yahoo3 days agoLLY
FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Benzinga3 days agoLLY
Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs
Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
Yahoo3 days agoLLY
Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal
Merida's lead programme, MER511, is in Phase I development for Graves' disease and thyroid eye disease (TED).
Yahoo3 days agoLLY
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More
Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform. Click here for more.
SeekingAlpha8 days agoLLY
Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.
Benzinga9 days agoLLY
Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week
Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.
Benzinga9 days agoLLY
Wall Street Lunch: Meta Settles Minors' Addiction, Data Privacy Claims For $12.7B
Meta Platforms (META) has reached a settlement with state attorneys general over allegations that Facebook and Instagram were intentionally designed to be addictive to minors.
SeekingAlpha9 days agoLLY
Eli Lilly (NYSE:LLY) Demonstrates High-Growth Leadership and Momentum
Eli Lilly (LLY) passes the CAN SLIM screen with strong earnings, sales growth, high relative strength, and bullish technicals. Learn more.
ChartMill9 days agoLLY
Ohio Rep. Michael Rulli Sold Up to $100K Worth of Alphabet Stock
An official report on August 25, 2026 reveals Representative Michael Rulli's recent sale of Alphabet (NASDAQ:GOOGL) stock, valued between $50,001 and $100,000. The transaction took place on August 24, 2026, as per
Benzinga9 days agoLLY
Amplitude Therapeutics Partners With Eli Lilly Over Discovery, Development Of taRNA Vaccine Candidates For Infectious Diseases
Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, today announced a strategic research collaboration and licensing agreement with Eli Lilly and Company
Benzinga16 days agoLLY
Novo Nordisk: The Best Value In Pharma
SeekingAlpha16 days agoLLY
'Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills' - WSJ
https://www.wsj.com/health/pharma/novo-nordisk-starts-testing-lower-doses-of-its-wegovy-weight-loss-pills-8896fec2
Benzinga16 days agoLLY
Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC’s ‘Final Trades’
Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.
Benzinga16 days agoLLY
Top 3 Health Care Stocks That Could Blast Off This Month
The health care sector's oversold stocks present buying opportunities for undervalued companies. RSI compares stock strength on up and down days, with an RSI below 30 considered oversold.
Benzinga16 days agoLLY
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Benzinga17 days agoLLY
From The ETF Professor: NFLX content deal helps SKYY, cloud computing ETF, hit high of the day. NFLX 6.6% of ETF's weight
Benzinga17 days agoLLY
5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call
Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited growth in key products—especially in cardiometabolic health, oncology, and neuroscience—as drivers of performance. CEO David Ricks pointed to “robust revenue growth across all Key Products and major geographies,” noting the strength of new medicines and expansion in emerging markets. The launch of Foundayo in the U.S. and UAE, along with ongoing
Yahoo21 days agoLLY
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
Novo argues that differentiated treatments--not a single dominant drug--will determine its position against Eli Lilly.
Yahoo21 days agoLLY
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity
The stock continues to look unstoppable.
Yahoo21 days agoLLY
Novo Nordisk Escalates Weight-Loss War With Eli Lilly
A marketing dispute could reshape a crucial competitive advantage
Yahoo21 days agoLLY
European Stocks Close Mixed in Thursday Trading; UK GDP Growth Slows in Q2
The European stock markets closed mixed in Thursday trading as The Stoxx Europe edged 0.1% lower, Ge
Yahoo22 days agoLLY
Eli Lilly (LLY) Q2 2026 Earnings Call Transcript
Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.
Yahoo22 days agoLLY
Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps
Novo Nordisk's CEO conceded Eli Lilly is gaining market share even as oral Wegovy hits record prescriptions and the stock keeps falling.
Yahoo22 days agoLLY
How ABBV Stock Moved Away From Its Peer Group
The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.
Yahoo22 days agoLLY
Eli Lilly takes weight-loss pill battle global with first Foundayo approval in Europe
Lilly's Foundayo wins U.K. approval, taking its weight-loss pill battle with Novo Nordisk's Wegovy beyond the U.S. market.
CNBC24 days agoLLY
Cramer’s Analyst Says Eli Lilly’s GLP-1 Stock Rally Has Years Left to Run
Jeff Marks and Jim Cramer say Eli Lilly's GLP-1 stock rally has years left, backed by surging global demand.
Yahoo24 days agoLLY
Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions
Eli Lilly’s updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay updated as...
Yahoo24 days agoLLY
What Analysts Really Pressed LLY On This Quarter
Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.
Yahoo24 days agoLLY
Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?
For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of […]
Yahoo24 days agoLLY
Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill
Foundayo secured its first European authorization, extending Lilly's obesity portfolio beyond injectable medicines
Yahoo24 days agoLLY
Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY
During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]
Yahoo24 days agoLLY
Sector Update: Healthcare Stocks Rise in Afternoon Trading
Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State
Yahoo24 days agoLLY
Eli Lilly’s GLP-1 Pill Secures First European Milestone – Here’s Everything To Know About UK MHRA’s Foundayo Approval
The U.K.’s Medicines and Healthcare products Regulatory Agency approved Foundayo for weight loss and maintenance in adults with obesity, as well as certain overweight adults with at least one weight-related health condition.
Yahoo24 days agoLLY
Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection
The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.
Yahoo24 days agoLLY
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.
Yahoo25 days agoLLY
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.
New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.
Yahoo25 days agoLLY
Lifespan Vision Ventures Leads Remedium Bio's Series A Financing
Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's initial closing, with participation from Eli Lilly and Company ("Lilly") and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Directors.
Yahoo25 days agoLLY
Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook
Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and profit targets. Shares moved higher the same day as investors focused […]
Yahoo26 days agoLLY
CVS Health (CVS) Is Down 8.6% After Raising 2026 Guidance And Expanding GLP-1 Tie-Up With Lilly – Has The Bull Case Changed?
In early August 2026, CVS Health reported second-quarter results showing higher sales of US$35,117 million and revenue of US$106.10 billion, alongside net income of US$2,979 million and materially higher earnings per share versus a year earlier. On the same day, CVS Health also raised its 2026 earnings guidance and expanded its GLP-1 weight management offering through a new collaboration with Eli Lilly, underscoring how integrated pharmacy, insurance and care-delivery assets can be combined...
Yahoo28 days agoLLY
Why Is Everyone Talking About Novo Nordisk?
The drugmaker continues to face headwinds.
Yahoo28 days agoLLY
Novo Nordisk faces a rough patch
Novo’s shares have fallen 15% this year, tumbling further this week after guidance missed analysts’ targets.
Yahoo28 days agoLLY
Eli Lilly: Fine Q2 2026 Results, But Alertness Required
Eli Lilly's stock jumps 5% on strong earnings and raised revenue guidance. Click here to read more about LLY.
SeekingAlpha28 days agoLLY
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
Eli Lilly and Company will release its second-quarter earnings report before the opening bell on Wednesday, Aug. 5. Analysts expect the company to report quarterly earnings of $6.58 per share, up from $6.31 per share in the year-ago period. The...
Yahoo29 days agoLLY
Eli Lilly Q2: Strong Results Further Strengthen The Investment Thesis
Eli Lilly raised 2026 revenue guidance to $85â87B, driven by volume gains despite price declines, and reinforced margin expansion. Read why LLY stock is a Buy.
SeekingAlpha29 days agoLLY
3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations
As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.
Yahoo29 days agoLLY
Eli Lilly (LLY) Wins FDA Breakthrough Tag For Olomorasib, Is The Stock Still Cheap?
Eli Lilly (LLY) stock is back in focus after the FDA granted Breakthrough Therapy designation to its investigational drug olomorasib for KRAS G12C-mutant advanced pancreatic cancer, highlighting an expanding oncology effort. See our latest analysis for Eli Lilly. Eli Lilly’s share price has eased recently, with a 7 day share price return down 8.60% and a 30 day share price return down 8.09%. This is even though the 1 year total shareholder return sits at 46.69% and the 5 year total...
Yahoolast monthLLY
Dow Jones Futures Rise; SpaceX, AMD, Arista Lead Earnings Movers After S&P 500 Jumps To High
The Dow and S&P 500 hit new highs while the Nasdaq powered higher again. SpaceX, AMD and Arista led earnings movers late.
Yahoolast monthLLY